SE400083B - Forfarande for framstellning av humant karcinoembryonalt antigen - Google Patents

Forfarande for framstellning av humant karcinoembryonalt antigen

Info

Publication number
SE400083B
SE400083B SE7106985A SE698571A SE400083B SE 400083 B SE400083 B SE 400083B SE 7106985 A SE7106985 A SE 7106985A SE 698571 A SE698571 A SE 698571A SE 400083 B SE400083 B SE 400083B
Authority
SE
Sweden
Prior art keywords
human
procedure
manufacture
carcinoembryonal antigen
carcinoembryonal
Prior art date
Application number
SE7106985A
Other languages
English (en)
Swedish (sv)
Inventor
H J Hansen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SE400083B publication Critical patent/SE400083B/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J47/00—Ion-exchange processes in general; Apparatus therefor
    • B01J47/02—Column or bed processes
    • B01J47/04—Mixed-bed processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/26—Cation exchangers for chromatographic processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J47/00—Ion-exchange processes in general; Apparatus therefor
    • B01J47/014—Ion-exchange processes in general; Apparatus therefor in which the adsorbent properties of the ion-exchanger are involved, e.g. recovery of proteins or other high-molecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/825—Pretreatment for removal of interfering factors from sample
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SE7106985A 1970-06-01 1971-05-28 Forfarande for framstellning av humant karcinoembryonalt antigen SE400083B (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4252670A 1970-06-01 1970-06-01
US11028871A 1971-01-27 1971-01-27
US13340471A 1971-04-12 1971-04-12

Publications (1)

Publication Number Publication Date
SE400083B true SE400083B (sv) 1978-03-13

Family

ID=27366145

Family Applications (5)

Application Number Title Priority Date Filing Date
SE7106985A SE400083B (sv) 1970-06-01 1971-05-28 Forfarande for framstellning av humant karcinoembryonalt antigen
SE7413187A SE419482B (sv) 1970-06-01 1974-10-18 Sett att pavisa karcinoembryonala antigenmaterial i blod
SE7413184A SE421425B (sv) 1970-06-01 1974-10-18 Sett att renframstella karcinoembryonalt antigen med anvendning av en blanbeddsjonbytarkolonn
SE7413185A SE419481B (sv) 1970-06-01 1974-10-18 Karcinoembryonala antigener och dess radiojoderade former till anvendning som reagens vid bestemning av dessa antigener i blod
SE7413186A SE397139B (sv) 1970-06-01 1974-10-18 Sett att pavisa karoninoembryonalt antigen i blod medelst radioimmunoanalysteknik

Family Applications After (4)

Application Number Title Priority Date Filing Date
SE7413187A SE419482B (sv) 1970-06-01 1974-10-18 Sett att pavisa karcinoembryonala antigenmaterial i blod
SE7413184A SE421425B (sv) 1970-06-01 1974-10-18 Sett att renframstella karcinoembryonalt antigen med anvendning av en blanbeddsjonbytarkolonn
SE7413185A SE419481B (sv) 1970-06-01 1974-10-18 Karcinoembryonala antigener och dess radiojoderade former till anvendning som reagens vid bestemning av dessa antigener i blod
SE7413186A SE397139B (sv) 1970-06-01 1974-10-18 Sett att pavisa karoninoembryonalt antigen i blod medelst radioimmunoanalysteknik

Country Status (13)

Country Link
US (1) US3697638A (de)
JP (1) JPS542247B1 (de)
BE (1) BE767801A (de)
CA (1) CA965351A (de)
CH (4) CH596554A5 (de)
DE (1) DE2126680B2 (de)
DK (1) DK132739C (de)
FR (1) FR2095644A5 (de)
GB (4) GB1356912A (de)
IL (1) IL36950A (de)
IT (1) IT998033B (de)
NL (1) NL161457C (de)
SE (5) SE400083B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867363A (en) * 1970-06-01 1975-02-18 Hans John Hansen Carcinoembryonic antigens
CH583036A5 (de) * 1972-05-12 1976-12-31 Hoffmann La Roche
US3956258A (en) * 1972-05-12 1976-05-11 Hoffmann-La Roche Inc. Carcinoembryonic antigens
ZA723264B (en) * 1972-10-13 1974-08-28 H Van Til Improvements in toys
US3867518A (en) * 1973-03-09 1975-02-18 Hoffmann La Roche Radioimmunoassay for insulin
US3927193A (en) * 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US4022876A (en) * 1973-06-21 1977-05-10 Stanford Research Institute Mass spectrometric immunoassay
US4132769A (en) * 1974-10-30 1979-01-02 Osther Kurt B Cancer antigen, cancer therapy, and cancer diagnosis
US4152410A (en) * 1975-09-03 1979-05-01 Eisai Co., Ltd. Diagnosis reagent for neoplasm and method for diagnosis of neoplasm
US4132767A (en) * 1976-04-05 1979-01-02 Eisai Co., Ltd. Preparation of α-L antibody, purification of α-L antigen and reagent for detection of α-L antibody and α-L antigen
US4144031A (en) * 1976-04-19 1979-03-13 International Radioimmune Systems, Inc. Cell test for detecting human chorionic gonadotropin
US4145336A (en) * 1976-04-30 1979-03-20 Scripps Clinic And Research Foundation Carcinoembryonic antigen isomer
US4140753A (en) * 1976-04-30 1979-02-20 Scripps Clinic & Research Foundation Diagnostic method and reagent
US4146603A (en) * 1977-02-18 1979-03-27 Research Corporation Tumor specific glycoproteins and method for detecting tumorigenic cancers
US4234476A (en) * 1978-03-07 1980-11-18 Research Corporation Application of protein-protein interaction as an assay for the detection of cancer
US4228127A (en) * 1978-10-06 1980-10-14 International Radioimmune Systems, Inc. Kit for detecting human chorionic gonadotropin
US4241044A (en) * 1978-12-28 1980-12-23 Abbott Laboratories Method of diagnosing cancer by detecting elevated anti-T antibody activity
US4349528A (en) * 1979-11-21 1982-09-14 The Wistar Institute Monocolonal hybridoma antibody specific for high molecular weight carcinoembryonic antigen
US4299815A (en) * 1980-02-08 1981-11-10 Hoffmann-La Roche Inc. Carcinoembryonic antigen determination
US4578349A (en) * 1982-04-08 1986-03-25 Abbott Laboratories Immunoassay for carcinoembryonic antigen (CEA)
ATE28937T1 (de) * 1982-08-09 1987-08-15 Centocor Inc Immunotest fuer kohlehydrat-antigen-determinant.
DK557483A (da) * 1982-12-06 1984-06-07 Hoffmann La Roche Fremgangsmaade til bestemmelse af cea
US4962187A (en) * 1984-11-28 1990-10-09 Cota Biotech Common antigen for colorectal and mucinous ovarian tumors and process for isolating the same
US5030559A (en) * 1986-04-01 1991-07-09 Board Of Regents, The University Of Texas System Methods and compositions for the identification of metastatic human tumors
US6013772A (en) * 1986-08-13 2000-01-11 Bayer Corporation Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays
US5217903A (en) * 1990-05-15 1993-06-08 Trustees Of Boston University Measuring connective tissue breakdown products in body fluids

Also Published As

Publication number Publication date
BE767801A (fr) 1971-11-29
JPS542247B1 (de) 1979-02-05
CH595636A5 (de) 1978-02-15
GB1356911A (en) 1974-06-19
IL36950A (en) 1975-04-25
DE2126680A1 (de) 1971-12-09
SE419482B (sv) 1981-08-03
IT998033B (it) 1976-01-20
SE7413187L (de) 1974-10-18
CA965351A (en) 1975-04-01
SE421425B (sv) 1981-12-21
DE2126680B2 (de) 1980-10-09
FR2095644A5 (de) 1972-02-11
IL36950A0 (en) 1971-11-29
CH606067A5 (de) 1978-10-13
GB1356912A (en) 1974-06-19
DK132739B (da) 1976-02-02
GB1358827A (en) 1974-07-03
NL7107499A (de) 1971-12-03
NL161457B (nl) 1979-09-17
GB1358828A (en) 1974-07-03
SE7413186L (de) 1974-10-18
US3697638A (en) 1972-10-10
SE419481B (sv) 1981-08-03
CH596554A5 (de) 1978-03-15
CH604665A5 (de) 1978-09-15
NL161457C (nl) 1980-02-15
SE397139B (sv) 1977-10-17
DK132739C (da) 1976-07-12
SE7413184L (de) 1974-10-18
SE7413185L (de) 1974-10-18

Similar Documents

Publication Publication Date Title
SE400083B (sv) Forfarande for framstellning av humant karcinoembryonalt antigen
SE393381B (sv) Analogiforfarande for framstellning av 8-azapurin - 6 - onderivat
SE390304B (sv) Analogiforfarande for framstellning av 4-hydroxi-5-etyl-6-fonylpyrimidin
NO140731C (no) Fremgangsmaate for fremstilling av dimetyleter
SE384368B (sv) Forfarande for framstellning av 6-substituerade - 4 - amino- 1,2 - dihydro - 1 - hydroxi - 2 - iminopyrimidiner
SE7409801L (sv) Forfarande for framstellning av kinolinforeningar.
NO138883C (no) Fremgangsmaate for fremstilling av oksiranforbindelser
RO71354A (ro) Procedeu pentru prepararea unor p-halofenil-2-pirolidinone
SE388422B (sv) Forfarande for reduktion av theabin
SE382053B (sv) Forfarande for framstellning av bifenylylalkanoylaminopyridiner
SE399701B (sv) Forfarande for framstellning av hydroxyalkyldiamin
SE383151B (sv) Forfarande for framstellning av 1-hydroxi-2-pyridoner
SE394436B (sv) Forfarande for framstellning av 7-halogen-linkomyciner
SE380273B (sv) Forfarande for framstellning av tiopyrimidinderivat
SE385011B (sv) Forfarande for framstellning av alfa-linkosaminider
SE389105B (sv) Forfarande for framstellning av vissa angivna ketaziner
SE393111B (sv) Forfarande for framstellning av d-2-halogen-6-metyl-8-substituerad - ergolin
SE380272B (sv) Forfarande for framstellning av n-fosfonmetylglycin
SE408418B (sv) Forfarande for framstellning av 5-fluor-pyrimidiner
SE395699B (sv) Forfarande for framstellning av kinuklidin-kinolinderivat
FI56830B (fi) Foerfarande foer framstaellning av asparaginylgrupper innehaollande biologiskt aktiva polypeptider
SE393808B (sv) Forfarande for framstellning av isomaltit
SE391717B (sv) Forfarande for framstellning av 4-aryl-5-aminoalkyl-4-oxazolin-2-oner
SE380795B (sv) Forfarande for framstellning av tiokarbamider
SE411759B (sv) Forfarande for framstellning av erytromycyliminforeningar